Refractory Glioma: Clinical Trials

5 trials for Refractory Glioma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 2 completed. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Active not recruiting 3, Completed 2

Follow Refractory Glioma: new trials by email Literature Review of Refractory Glioma trials Research Report on Refractory Glioma

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor
Phase 2Active not recruitingNational Cancer Institute (NCI)202018-11-142026-11-13
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Phase 2CompletedNational Cancer Institute (NCI)232018-08-132026-04-03
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)62017-09-142024-12-11
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma
Phase 2Active not recruitingNational Cancer Institute (NCI)92017-08-232026-11-13
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2Active not recruitingNational Cancer Institute (NCI)13772017-07-312026-11-13

Narrower conditions

Ependymoma (5)  ·  Glioma (5)  ·  Hepatoblastoma (5)  ·  Histiocytosis, Langerhans-Cell (5)  ·  Lymphoma, Non-Hodgkin (5)  ·  Medulloblastoma (5)  ·  Neuroblastoma (5)  ·  Neuroectodermal Tumors, Primitive, Peripheral (5)  ·  Osteosarcoma (5)  ·  Rhabdoid Tumor (5)  ·  Rhabdomyosarcoma (5)  ·  Sarcoma (5)  ·  Wilms Tumor (5)  ·  Central Nervous System Neoplasms (3)  ·  Sarcoma, Ewing (3)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Female Urogenital Diseases (5)  ·  Female Urogenital Diseases and Pregnancy Complications (5)  ·  Genetic Diseases, Inborn (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Histiocytosis (5)  ·  Immune System Diseases (5)  ·  Immunoproliferative Disorders (5)  ·  Kidney Diseases (5)  ·  Kidney Neoplasms (5)  ·  Lung Diseases (5)  ·  Lung Diseases, Interstitial (5)  ·  Lymphatic Diseases (5)  ·  Lymphoma (5)  ·  Lymphoproliferative Disorders (5)

Interventions

Biopsy (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  Nuclear Medicine Department, Hospital (2)  ·  Phantoms, Imaging (2)  ·  Specimen Handling (2)  ·  X-Rays (2)  ·  larotrectinib (2)  ·  olaparib (2)  ·  palbociclib (2)  ·  ulixertinib (2)  ·  LY3023414 (1)  ·  Pharmacogenomic Variants (1)  ·  Vemurafenib (1)  ·  ensartinib (1)  ·  erdafitinib (1)

Sponsors

National Cancer Institute (NCI) (5)

Countries

Puerto Rico (5)  ·  United States (5)  ·  Australia (1)  ·  Canada (1)

Top investigators

Donald W Parsons (1)  ·  Julia Glade-Bender (1)  ·  Katherine A Janeway (1)  ·  Kieuhoa T Vo (1)  ·  Rajen Mody (1)

Results publications

PMID 31401903, PMID 33591402, PMID 35353553, PMID 38815151, PMID 38935895, PMID 39298716, PMID 41166674, PMID 42686334

NIH funding

U10CA180886 (5)